HSCS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.360

Open

3.280

VWAP

3.00

Vol

9.00K

Mkt Cap

10.00M

Low

3.260

Amount

31.00K

EV/EBITDA(TTM)

--

Total Shares

3.00M

EV

9.00M

EV/OCF(TTM)

--

P/S(TTM)

579.00

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.

Show More

Events Timeline

(ET)

2026-01-29

08:40:00

HeartSciences Partners with Cibolo Health to Promote MyoVista Insights

2025-12-15 (ET)

2025-12-15

08:40:00

HeartSciences Submits MyoVista wavECG Device for FDA 510(k) Clearance

2025-12-11 (ET)

2025-12-11

08:50:00

HeartSciences Launches MyoVista Insights Version 1.1

2025-06-04 (ET)

2025-06-04

09:02:30

HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm

2025-06-03 (ET)

2025-06-03

09:03:11

HeartSciences announces grant by USPTO for ECG assessment of heart function

2025-05-29 (ET)

2025-05-29

09:03:11

HeartSciences signs first MyoVista Insights platform customer

2025-05-07 (ET)

2025-05-07

09:03:33

HeartSciences appoints Nadkarni, Lampart, Vai to Scientific Advisory Board

2025-05-01 (ET)

2025-05-01

09:03:51

HeartSciences launches MyoVista Insights platform

2025-03-10 (ET)

2025-03-10

09:08:13

HeartSciences engages Integrous Communications to enhance communications

2024-09-12 (ET)

2024-09-12

16:21:04

Heart Test Laboratories announces financing, with $1.9M in net proceeds

News

an image of Newsfilter

01-29Newsfilter

HeartSciences Partners with Cibolo Health for ECG Management

an image of Globenewswire

2025-12-15Globenewswire

HeartSciences Submits MyoVista Device to FDA, Advancing AI ECG Technology

an image of Newsfilter

2025-12-15Newsfilter

HeartSciences Submits MyoVista Device for FDA 510(k) Clearance

an image of Benzinga

2025-10-01Benzinga

Ascendiant Capital Reaffirms Buy Rating on HeartSciences, Reduces Price Target to $9

an image of Newsfilter

2025-09-11Newsfilter

HeartSciences Shares Business Update and Announces Financial Results for First Quarter of Fiscal 2026

an image of Globenewswire

2025-08-18Globenewswire

Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open

2 Analyst Rating

Wall Street analysts forecast HSCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSCS is 10.60 USD with a low forecast of 9.20 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.20

Averages

10.60

High

12.00

Current: 0.000

Low

9.20

Averages

10.60

High

12.00

Ascendiant Capital

Lucas Ward

Strong Buy

Maintains

$15 → $14

AI Analysis

2025-03-18

Reason

Ascendiant Capital

Lucas Ward

Price Target

$15 → $14

AI Analysis

2025-03-18

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for HeartSciences Inc (HSCS.O) is -0.92, compared to its 5-year average forward P/E of -1.19. For a more detailed relative valuation and DCF analysis to assess HeartSciences Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-1.19

Current PE

-0.92

Overvalued PE

-0.26

Undervalued PE

-2.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-0.90

Current EV/EBITDA

-0.86

Overvalued EV/EBITDA

-0.00

Undervalued EV/EBITDA

-1.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

220.42

Current PS

33.27

Overvalued PS

1208.78

Undervalued PS

-767.93

Financials

AI Analysis

Annual

Quarterly

Whales Holding HSCS

Trading Trends

People Also Watch

Frequently Asked Questions

What is HeartSciences Inc (HSCS) stock price today?

The current price of HSCS is 3.34 USD — it has increased 2.14 % in the last trading day.

What is HeartSciences Inc (HSCS)'s business?

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.

What is the price predicton of HSCS Stock?

Wall Street analysts forecast HSCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSCS is10.60 USD with a low forecast of 9.20 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is HeartSciences Inc (HSCS)'s revenue for the last quarter?

HeartSciences Inc revenue for the last quarter amounts to 2.00K USD, decreased % YoY.

What is HeartSciences Inc (HSCS)'s earnings per share (EPS) for the last quarter?

HeartSciences Inc. EPS for the last quarter amounts to -0.85 USD, decreased -62.56 % YoY.

How many employees does HeartSciences Inc (HSCS). have?

HeartSciences Inc (HSCS) has 15 emplpoyees as of January 30 2026.

What is HeartSciences Inc (HSCS) market cap?

Today HSCS has the market capitalization of 10.00M USD.